NATICK, Mass. and PARIS, May 20, 2011 /PRNewswire/ — Boston
Scientific Corporation (NYSE:
BSX) today announced 12-month results from its PLATINUM Small
Vessel study, demonstrating excellent safety and effectiveness
outcomes for the 2.25 mm PROMUS Element™ Everolimus-Eluting
Platinum Chromium Stent System in treating small vessel coronary
disease.  The study is a global, prospective, single-arm,
subtrial of the PLATINUM clinical program.  It compares the
PROMUS Element Stent (2.25 mm) in 94 patients with small vessels
(greater than or equal to 2.25 to less than 2.50 mm reference
vessel diameter and less than or equal to 28 mm lesion length) to a
pre-specified performance goal based on results from patients
treated with the TAXUS® Express® Paclitaxel-Eluting
Stent.

Analysis of the data was presented at the annual EuroPCR
Scientific Program in Paris by Ian T. Meredith, M.B.B.S., Ph.D.,
Professor of Cardiology and Medicine, Monash University, and
Executive Director of Monash Cardiovascular Research Center, Monash
Medical Centre, Clayton, Victoria, Australia, and Co-Principal
Investigator for the PLATINUM clinical program.

“The PLATINUM Small Vessel data demonstrate exceptionally low
rates of revascularization, while reporting no myocardial
infarction or stent thrombosis at one year in patients treated with
the 2.25 mm PROMUS Element Stent,” said Professor Meredith.
 “These results are impressive, especially considering the
small vessel diameter in this patient population.”

The PLATINUM Small Vessel study met its primary endpoint of
target lesion failure (TLF) at 12 months with a rate of 2.4 percent
for the 2.25 mm PROMUS Element Stent in the per protocol population
compared to a pre-specified performance goal of 21.1 percent
(p<0.001) based on historical outcomes for the 2.25 mm TAXUS
Express Stent.  Components of TLF in the p

‘/>”/>

SOURCE